Targeting mu opioid receptors to modulate gastrointestinal function: what have we learnt so far from the studies in functional bowel disorders? by Corsetti, Maura et al.
 Open Peer Review
F1000 Faculty Reviews are commissioned
from members of the prestigious F1000
. In order to make these reviews asFaculty
comprehensive and accessible as possible,
peer review takes place before publication; the
referees are listed below, but their reports are
not formally published.
Any comments on the article can be found at
the end of the article.
REVIEW
Targeting mu opioid receptors to modulate gastrointestinal
function: what have we learnt so far from the studies in
 functional bowel disorders? [version 1; referees: 2 approved]
Maura Corsetti ,   Jasper Pannemans , Peter Whorwell4
NIHR Nottingham Biomedical Research Centre (BRC), Nottingham University Hospitals NHS Trust and the University of Nottingham,
Nottingham, UK
Nottingham Digestive Diseases Centre, School of Medicine, University of Nottingham, Nottingham, UK
Catholic University of Leuven, KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium
Centre for Gastrointestinal Sciences, University of Manchester, Manchester, UK
Abstract
Opioids have recently received much attention because of the epidemic in their
use in some countries such as the USA and the UK. Concerns have been
raised about the possibility that they can increase mortality in patients when
used on a long-term basis. Moreover, they are known to induce paradoxical
hyperalgesia as well as alterations of gut function. The analgesic properties of
opioids are mediated by receptors located in the brain, but as opioid receptors
are also expressed in the gastrointestinal tract, new drugs acting on these
receptors have recently been developed to treat two functional disorders,
namely irritable bowel syndrome with diarrhoea and opioid-induced
constipation. The aim of this article is to highlight some interesting observations
resulting from the development of these drugs in the field of functional
gastrointestinal disorders.
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Introduction
Opioids have recently received much attention because of the 
epidemic in their use in some countries such as the USA and 
the UK. They are the most commonly prescribed class of 
drugs to treat chronic pain, particularly non-cancer pain, in the 
USA1. Concerns about the possible increased mortality associated 
with the use of these medications and the paradoxical hyperalgesia 
they can induce have raised questions about their role in the 
management of non-cancer pain, particularly when used on a long-
term basis2. The analgesic properties of opioids are mediated by 
receptors located in the brain, but as opioid receptors are also 
expressed in the gastrointestinal (GI) tract, new drugs acting 
on these receptors have recently been developed to treat irrita-
ble bowel syndrome with diarrhoea (IBS-D) and opioid-induced 
constipation (OIC). In a recent article two of the co-authors of 
the present article reviewed the data concerning these new drugs3. 
The aim of this review is to highlight some interesting observa-
tions resulting from the development of these drugs in the field 
of functional gastrointestinal disorders.
What do we know about the effect of opioids on 
gastrointestinal function?
µ, κ, δ, and opioid receptor-like-1 (ORL-4)4 receptors are 
G protein–coupled receptors found in the central nervous system. 
In the GI tract, at the site of µ, κ and δ receptors3, opioids are able 
to bind to opioid receptors.
Most of the GI effects seem to be mediated by the high number 
of µ-receptors expressed on neurons of the enteric nervous 
system4,5. In general, opioids have been demonstrated to reduce 
gut transit by stimulating non-propulsive contractions and increas-
ing the tone of gut sphincters5. Opioids have been associated with 
increased lower oesophageal sphincter (LOS) resting pressure, 
decreased LOS relaxation, and reduced number of transient LOS 
relaxations6. Opioids have been demonstrated to delay both 
gastric emptying and small bowel transit as well as to impair 
bile duct flow, possibly as a result of increased frequency in 
sphincter of Oddi contractions5. Opioids cause decreased colonic 
propulsion through inhibition of excitatory neural pathways as 
well as inhibition of inhibitory neural pathways leading to non-
propulsive colonic motility, eventually resulting in constipa-
tion. In addition, they lead to concomitant inhibition of electro-
lyte and water secretion and increased absorption of water and 
electrolytes5. At the distal end of the colon, opioids have also 
been shown to increase the rectal distension threshold for first 
perception and for inducing recto-anal inhibitory reflex6. 
The effect of opioid receptor activation on gut motility has 
been attributed to the pre-synaptic inhibition of the release of 
excitatory transmitters from neurons governing smooth mus-
cle contractions6. However, studies on animal and human colons 
have demonstrated that inhibition of inhibitory neuromuscu-
lar transmission may also play a role6. Interestingly, although 
most of the effects induced by opioids exhibit tolerance, this does 
not seem to be the case for GI consequences6. Recent studies 
have suggested that this could be due to differences or alterations 
of the receptor signalling mechanisms in enteric as compared 
with central neurons during prolonged opioid use6.
What have we learnt from the use of mu opioid 
receptor agonists in the treatment of diarrhoea in 
irritable bowel syndrome?
IBS is a functional GI disorder characterised by the presence of 
recurrent abdominal pain associated with abnormal stool fre-
quency and form7. In addition, the majority of patients complain 
of abdominal bloating, which often is accompanied by visible 
distension of the abdomen. The prevalence of IBS is about 10% 
in Western countries, and owing to its chronic relapsing course, it 
represents a major cost to healthcare resources as these patients 
use healthcare services more than the general population7,8. 
Patients with IBS-D represent about one third of the IBS popu-
lation and, compared with patients who have IBS with constipa-
tion, experience more pain attacks, abdominal pain that is more 
related to bowel movements, more urgency, a less stable bowel 
habit, and less bloating7,8.
The treatment of IBS is normally based on reassurance and edu-
cation coupled with dietary and lifestyle advice8. The traditional 
pharmacological treatment of IBS-D includes the combination 
of drugs acting on pain (antispasmodics) and diarrhoea (lopera-
mide), and antidepressants are used for those not responding to 
initial therapy. Recently, both the US Food and Drug Adminis-
tration (FDA) and the European Medicines Agency (EMA) have 
approved eluxadoline, a mixed µ- and κ-opioid receptor agonist 
and δ-opioid receptor antagonist, for the treatment of IBS-D.
Eluxadoline is not the first µ-opioid receptor agonist used in 
IBS-D. Loperamide, an opiate analogue of the piperidine class 
with low bioavailability, has been used to treat acute and chronic 
diarrhoea for over three decades. Owing to its µ-opioid receptor 
agonist activity, loperamide has limited penetration of the 
blood–brain barrier and inhibits GI peristalsis and secretion9. 
In total, four trials have evaluated the efficacy of loperamide 
in IBS patients with diarrhoea or mixed stool patterns10. Lop-
eramide showed an effect on stool consistency, urgency and 
bowel frequency, associated with delay in both small bowel and 
whole gut transit time. Although some trials have demonstrated 
pain reduction, systematic reviews do not advocate the use of 
loperamide in IBS-D owing to insufficient evidence10. Despite 
this, in clinical practice, loperamide is the most commonly used 
drug for IBS-D. Side effects of loperamide include nausea, 
vomiting, constipation, dry mouth, dizziness, and abdominal 
discomfort10. Recent warnings have reported that abuse or mis-
use of loperamide at very high doses can lead to cardiac adverse 
events (AEs)11.
Eluxadoline is a phenylimidazole with mixed opioid receptor 
activity, acting as a µ-opioid receptor agonist with a binding 
affinity (Ki) of 1.8 nmol/L for the human receptor, a δ-opioid 
receptor antagonist with a Ki of 430 nmol/L for the human recep-
tor, and a κ-opioid receptor agonist with an as-yet-unknown 
Ki for the human receptor8. The exact mechanism of action of 
eluxadoline is unclear. However, studies have found that the antag-
onism of the δ-opioid receptor may enhance the analgesic effect 
of morphine, preventing the induction of tolerance, suggesting the 
presence of an interaction between the two receptors8.
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Two multicentre, double-blind, placebo-controlled, phase 3 stud-
ies, conducted in 2428 patients with IBS-D, have been reported12. 
These were 26-week studies followed by a 26-week follow-up 
period and a 2-week post-treatment follow-up period in one trial 
and by a 4-week withdrawal period in the other trial. Patients 
were considered to be “responders” when they experienced at 
least a 30% reduction from their baseline score of worst abdomi-
nal pain in at least 50% of the days and a stool consistency score 
of less than 5 on the Bristol stool scale over 12 and 26 weeks, 
respectively, according to the FDA and EMA endpoints.
The percentage of patients, defined as responders to twice-daily 
75 mg and 100 mg eluxadoline, according to the composite FDA 
endpoints, was higher as compared with placebo (23.9% and 
25.1% respectively versus 17.1%, p = 0.004; 28.9% and 28.9% 
respectively versus 16.2%, p <0.001). Furthermore, the percent-
age of patients, defined as responders according to the composite 
EMA endpoints, was significantly higher as compared with 
placebo, but in this case only for the 100-mg dose (29.3% versus 
19.0%, p <0.001 and 32.7% versus 20.2%, p <0.001). The number 
needed to treat for eluxadoline is 813.
Both doses showed superiority to placebo for stool consistency, 
frequency, urgency, adequate relief of IBS symptoms, global 
symptom scores, and scores on IBS-quality of life (IBS-QOL) 
questionnaires. However, when only the percentage of patients 
who reported an improvement of at least 30% in their worst 
abdominal pain was considered, this was not significantly higher 
than placebo.
A post-hoc analysis, focusing on loperamide use before and during 
the trials, revealed that about 36% of the patients reported prior 
use of loperamide and that 59% to 67% of these had inadequate 
IBS-D symptom control on loperamide14. Patients who reported 
adequate symptom control with earlier use of loperamide were 
more likely to be composite responders to eluxadoline com-
pared with placebo (44.3% versus 26.7% respectively, P <0.01). 
However, when daily rescue loperamide use was imputed as a 
non-response day, the composite responder rate was still higher 
in patients receiving eluxadoline as compared with placebo over 
weeks 1 to 12 and weeks 1 to 26 for both dosages.
The most common AEs when taking eluxadoline were nausea, 
constipation, and abdominal pain12. However, a more serious side 
effect of pancreatitis was reported in some patients participating 
in the pivotal trials.
In a recent editorial by Chedid et al.15, reviewing 1666 patients 
who received eluxadoline in the phase 3 trials, five developed 
acute pancreatitis: two on 75 mg and three on 100 mg. Further-
more, there have been 120 reports of pancreatitis or death in 
patients receiving eluxadoline made to the FDA via the Federal 
Adverse Events Reporting System (FAERS), a publicly acces-
sible reporting system. As a result, the FDA released a Drug 
Safety Communication warning detailing the heightened risk of 
pancreatitis with the use of eluxadoline in patients with IBS-D 
who had undergone prior cholecystectomy. The FDA declared 
previous cholecystectomy a contraindication for the use of 
eluxadoline in line with a previous recommendation by the 
EMA. Some incidents occurred after only one or a few doses 
of the drug. Acute pancreatitis has also been documented in 
cases where there was no prior cholecystectomy. These cases of 
pancreatitis following the use of eluxadoline were assumed to 
be the result of sphincter of Oddi spasm. The definition of pan-
creatitis was based on the Atlanta criteria, a universally applicable 
classification system for the diagnosis of acute pancreatitis based 
on clinical criteria and radiological criteria as well as clinical 
judgement. The problem with the FAERS is that it is a voluntary 
reporting system, making it difficult to calculate the true inci-
dence of pancreatitis in patients taking eluxadoline, especially as 
this problem can be seen with other drugs used for controlling 
diarrhoea in IBS, such as loperamide and other opiates. Con-
sequently, it would be useful to have a study evaluating the 
incidence of pancreatitis in patients taking loperamide and 
possibly other opiates, as not many clinicians are aware of this 
potential side effect. In order to possibly mitigate this problem 
with eluxadoline, a formulation designed to specifically target 
the colon is in development16. Alcoholism, alcohol abuse, alcohol 
addiction, and chronic or acute excessive alcohol use are other 
important contraindications because these patients already have 
an increased risk of acute pancreatitis.
The problem of side effects and in particular serious side effects, 
such as those reported for eluxadoline or in the past with the 
5-HT3 antagonist alosetron (ischemic colitis), is that IBS is usu-
ally considered a completely benign condition. However, it has 
been consistently shown that IBS can have a profound impact on 
the QOL of patients with IBS. Indeed, 13.5% of patients would 
be willing to accept at least a 1-in-1000 chance of death and 
10.1% would accept at least a 1-in-1000 risk of serious or per-
manent side effects from a medication to achieve perfect health17. 
Patients with the most severe IBS were the most likely to accept 
risk. In secondary and tertiary care, there is a relationship 
between IBS and significant suicide risk, which is not associated 
with any concurrent depression18.
Current evidence shows that eluxadoline is less likely to be 
abused than other schedule II µ-opioid receptor agonists among 
recreational opioid users. The use of supratherapeutic doses of 
oral or intranasal eluxadoline led to results not comparable to 
those observed with the use of the µ-agonist oxycodone (positive 
control),  although some small but significant differences from 
placebo were observed for some outcome measures. How-
ever, the therapeutic dose of eluxadoline was similar to placebo 
following oral administration and intranasal eluxadoline was 
generally associated with significant dislike versus placebo and 
oxycodone19.
What have we learnt from the use of mu opioid 
receptor antagonists in the treatment of opioid-
induced constipation?
As reported before, opioids are the most commonly prescribed 
class of drugs to treat chronic pain, particularly non-cancer 
pain. Based on a systematic review that included 15 randomised 
placebo-controlled trials20, the prevalence of OIC in patients 
taking opioids for chronic non-cancer pain is 41%. This disorder 
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was recently classified as part of the functional bowel disorders 
by the Rome Foundation and defined as “a change, when initiat-
ing opioid therapy, from baseline bowel habits and defecation 
patterns, that is characterised by any of the following: reduced 
bowel frequency; development or worsening of straining; a sense 
of incomplete evacuation; or a patient’s perception of distress 
related to bowel habits”7. The occasional patient may also develop 
faecal impaction with overflow incontinence, whereas others may 
report symptoms compatible with overlapping opioid-induced 
bowel disorders (for example, reflux nausea and bloating)7.
Although this disorder does not directly lead to an increase 
in mortality, it results in a reduction in QOL. In a recent cross- 
sectional analysis of an ongoing longitudinal study conducted in 
the USA, Canada, Germany and the UK on patients with self-
reported OIC on daily opioid therapy for at least 4 weeks for 
non-cancer pain, it was reported that constipation symptoms limit 
the work productivity and overall health-related QOL of these 
patients21. In a recent retrospective analysis in patients with 
non-cancer pain in the USA, it was demonstrated that among 
opioid users those with OIC generate significantly higher total 
healthcare costs as compared with those without22.
OIC is normally managed with treatments similar to those 
applied in functional constipation, including fibre, stimulant and 
osmotic laxatives, lubiprostone, linaclotide and prucalopride. 
However, laxatives have not been found to be better than placebo 
and the others do not target the mechanism of OIC6. Therefore, 
new drugs acting on µ-opioid receptors, including naloxegol, 
methylnaltrexone and naldemedine, have recently been developed 
to treat OIC. They are all peripherally acting µ-opioid receptor 
antagonists (PAMORA) and an oral formulation approved by 
the FDA and the EMA for this condition is available.
Naloxegol
Naloxegol is a PAMORA derived from the µ-opioid receptor 
antagonist naloxone and is the first oral medication approved by 
both the FDA and the EMA for the treatment of OIC in patients 
with non-cancer pain. Preclinical investigations showed the 
ability of naloxegol to accelerate GI transit time in morphine- 
induced constipation without affecting the analgesic effects of 
morphine23. Owing to PEGylation, attachment of polyethylene 
glycol causing P-glycoprotein transporter-substrate properties, the 
ability of naloxegol to cross the blood–brain barrier is limited23.
Two randomised, double-blind, 12-week, phase 3 trials were 
conducted in patients with OIC and non-cancer pain to assess 
the effect of naloxegol 25 mg and 12.5 mg as compared with 
placebo24,25. According to the FDA and EMA endpoints, a 
responder was defined as a patient experiencing at least three 
spontaneous bowel movements (SBMs) weekly, with an at least 
one-SBM increase over baseline in at least 9 out of 12 weeks and 
at least 3 out of 4 final weeks. In the KODIAC 04 study, both 
doses achieved a higher response rate (RR) compared with pla-
cebo (25 mg: RR 1.51, 95% confidence interval (CI) 1.17–1.95, 
p = 0.001 and 12.5 mg: RR 1.38, 95% CI 1.06–1.80, p = 0.02). In 
KODIAC 05, only the 25-mg dose achieved a significant difference 
compared with placebo (25 mg: RR 1.35, 95% CI 1.05–1.74, 
p = 0.02 and 12.5 mg: RR 1.19, 95% CI 0.91–1.55, p = 0.20). In 
the laxative-inadequate response (LIR) subpopulation (defined as 
patients “who took laxatives in one or more laxative classes for 
a minimum of 4 days within 2 weeks before screening and had 
ratings of moderate, severe, or very severe on one or more of the 
four stool-symptom domains in the baseline laxative-response 
questionnaire”24), which made up 53.9% of the total population, 
the 25-mg treatment group achieved a greater RR compared with 
placebo (KODIAC 04: RR 1.69 95% CI 1.21–2.37, p = 0.002 
and KODIAC 05: RR 1.49, 95% CI 1.08–2.06, p = 0.01)24. 
In addition, greater improvements were found with 25 mg 
naloxegol for straining, stool consistency, and frequency of days 
with SBM in both trials. Naloxegol was generally safe and well 
tolerated at a dose of 25 mg, and the most frequent AEs were 
GI-related, such as diarrhoea, abdominal pain and vomiting26,27. 
QOL was not measured in these trials.
Methylnaltrexone
N-methylnaltrexone bromide is a quaternary derivative of naloxone 
PAMORA. Naloxone is effective in antagonising the inhibitory 
responses of morphine on smooth muscle and accelerating GI 
transit time28–32. The quaternary functional unit decreases lipid 
solubility, resulting in blood–brain barrier passage restriction28. 
Methylnaltrexone is available as both subcutaneous and oral 
formulation. In healthy subjects, oral methylnaltrexone signifi-
cantly attenuated or completely prevented morphine-induced 
delay in oro-cecal transit time, depending on the dose.
A previous multicentre, double-blind, randomised controlled 
phase 3 trial, including 460 patients with non-cancer OIC, was 
conducted to compare the efficacy of subcutaneous methylnal-
trexone 12 mg once daily (QD) or every other day and placebo 
over 4 weeks32. The co-primary efficacy endpoints were the pro-
portion of patients having a rescue-free bowel movement (RFBM 
or bowel movement without previous assumption of rescue 
medication) within 4 hours of the first dose and the percent-
age of active injections per patient resulting in an RFBM within 
4 hours. A greater percentage of patients who received methyln-
altrexone QD or alternate-day dosing as compared with placebo 
were able to achieve an RFBM within 4 hours of the first 
dose (34.2% versus 9.9%, p <0.001). In addition, 28.9% of 
methylnaltrexone QD and 30.2% of methylnaltrexone alter-
nate-day dosing resulted in RFBMs within 4 hours versus 9.4% 
QD and 9.3% alternate-day placebo injections (both p <0.001). 
Most common AEs were abdominal pain, nausea, diarrhoea, 
hyperhidrosis and vomiting. It could be argued that having an 
RFBM within 4 hours of the first dose is not of clinical rele-
vance in a chronic condition, although this study also showed an 
improvement in QOL. At the end of the double-blind period 
(day 28), the methylnaltrexone QD group showed a significantly 
greater mean improvement of 0.74 (33%) from baseline in Patient 
Assessment of Constipation-QOL total scores compared with 
an improvement of 0.39 (18%) in patients receiving placebo 
(p <0.001). At day 28, the patients receiving methylnaltrexone 
every other day showed a mean improvement of 0.59 (27%) 
from baseline, which was significantly greater than that seen in 
the placebo group (p = 0.014)33.
Because of the reported risk of perforation in studies evaluat-
ing the effect of methylnaltrexone in patients with cancer, the 
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medication is not recommended to patients with OIC when it is 
associated with conditions of the GI tract potentially increasing 
this risk (that is, inflammation)34.
Recently, a multicentre, double-blind, randomised controlled 
phase 3 trial, including 804 patients with non-cancer OIC, was 
conducted to compare the efficacy of oral methylnaltrexone (150, 
300 or 450 mg) or placebo QD for 4 weeks followed by as-needed 
dosing for 8 weeks35. Patients who had at least three RFBMs 
per week, with an increase of at least one RFBM per week from 
baseline for at least 3 out of 4 weeks during the QD period, 
were responders. The percentage of responders (49.3% for 
300 mg and 51.5% for 450 mg versus 38.3% with placebo, all 
p <0.03) and change from baseline in mean number of weekly 
RFBMs (difference versus placebo, 0.5 for 300 mg and 0.5 for 
450 mg, all p <0.03) were significantly greater with meth-
ylnaltrexone 300 and 450 mg/day versus placebo during the 
QD period. AEs were mostly GI-related; abdominal pain, 
nausea and diarrhoea were the most frequently reported. In 2016, 
the oral tablet received FDA approval for use in patients with 
OIC. QOL was not measured in this trial.
Naldemedine
Naldemedine (S-297995) is a PAROMA that was approved 
by the FDA in 2017 for the treatment of OIC. Its structure is 
similar to that of naltrexone; however, it possesses an extra 
side chain, which increases its molecular weight and polar 
surface area, thereby limiting its ability to cross the blood–brain 
barrier36,37.
Two, 12-week, multicentre, phase 3 trials have been conducted 
to evaluate the efficacy of oral naldemedine 0.2 mg or matching 
placebo QD for 12 weeks in patients with chronic non-cancer 
pain35. In these studies, the same FDA and EMA endpoints 
employed in the naloxegol trials reported above were used21. In 
COMPOSE I and II, 547 and 553 patients, respectively, were 
assigned to naldemedine or placebo. In both trials, the percent-
age of responders was significantly greater in the naldemedine 
group compared with the placebo group (47.6% versus 34.6%, 
p = 0.002 in COMPOSE I and 52.5% versus 33.6%, p <0.001 
in COMPOSE II). The drug was well tolerated, although more 
GI AEs such as diarrhoea and abdominal pain were observed.
The long-term safety of naldemedine was subsequently evalu-
ated in 1246 patients with OIC and chronic non-cancer pain 
in a 52-week, randomised, double-blind, phase 3 study38. The 
proportion of patients experiencing a treatment-related AE was 
similar between the two groups (68.4% with naldemedine versus 
72.1% with placebo). Bowel movement frequency and over-
all constipation-related symptoms and QOL were improved 
with the use of naldemedine and these benefits did not affect 
opioid-mediated analgesia or necessitate opioid withdrawal.
Conclusions
IBS-D and OIC are two common disorders, which are chal-
lenging to treat and have a significant negative impact on the 
QOL of patients. The prevalence of OIC is likely to increase as 
a result of the ‘opioid epidemic’1 and therefore there is a strong 
need for better management strategies.
Eluxadoline is a welcome addition to the therapeutic options for 
IBS-D as there are currently very few pharmacological alterna-
tives. Currently, if loperamide is ineffective, ondansetron has 
been shown to be a good alternative10 but if that fails, codeine 
is the only other option but it carries the risk of dependency. In 
this situation, in a patient who is desperate for some improvement, 
eluxadoline should be considered and is probably relatively 
safe as long as the exclusion criteria are strictly adhered to 
and patients are fully informed about the possible side effects. 
The authors are accumulating real-world clinical experience of 
eluxadoline in tertiary-care patients refractory to all other medi-
cations and finding it very effective in a significant proportion 
of individuals with this challenging form of IBS.
Obviously, the best treatment for OIC would be to stop the use 
of opioids as a long-term therapy, especially as there is accumu-
lating evidence that opioids are ineffective in controlling non- 
cancer chronic pain syndromes. However, while trying to reduce 
this overuse, medications such as naloxegol, methylnaltrexone 
and naldemedine are welcome tools in helping to manage this 
problem, especially as they are relatively free of side effects. 
There have been no direct comparisons of these PAMORAs and 
therefore the choice of which one to use is likely to be based on 
what is currently available on the market in a particular country.
In light of the data accumulating in recent years on the use of 
opioids and µ-opioid receptor agonists and antagonists to modu-
late the GI function, some lessons can be learned. Opioid receptors 
have a significant impact on the function of the entire gut as 
demonstrated by preclinical studies which explain the side 
effects observed in clinical practice. It is clear from reviewing the 
activity of the drugs developed so far that worthwhile thera-
peutic effects can be achieved but, in some instances, at the 
expense of some AEs. Consequently, modulating opioid recep-
tors deserves further study, especially as, after many years of 
little progress, new techniques of assessing the physiology of the 
GI system are becoming available.
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